Don Dizon, MD of Massachusetts General Hospital discusses the use of novel agents in ovarian cancer. He states that Olaparib and Rucaparib are not FDA approved for clinical trials but are approved for use as a line of treatment for patients who succeeded with chemotherapy but relapsed. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Olaparib and Rucaparib in the Maintenance Setting for Ovarian Cancer
